GREENLAND MINES LTD (GRML) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.49M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$9.51M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$1.85M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$1.89M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$5.49M | (m) | (m) | (m) | (m) | -$6.85M* | (m) | $400.54K | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$9.51M | (m) | (m) | (m) | (m) | -$4.97M | (m) | $321.27K | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$1.85M | (m) | (m) | (m) | (m) | -$1.12M* | (m) | $271.14K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$1.89M | (m) | (m) | (m) | (m) | -$1.94M* | (m) | $238.70K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$1.59M | (m) | (m) | (m) | (m) | -$1.55M | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$2.87M | (m) | (m) | (m) | (m) | -$1.07M* | (m) | $0.00 | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$395.61K | (m) | (m) | (m) | (m) | -$907.42K* | (m) | $0.00 | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$672.04K | (m) | (m) | (m) | (m) | -$21.98K | (m) | $0.00 | (m) | $49.07K |
| 2023-09-30 | Reported | (m) | -$123.74K | (m) | (m) | (m) | (m) | $18.02K* | (m) | $0.00 | (m) | $148.85K |
| 2023-06-30 | Reported | (m) | -$244.25K | (m) | (m) | (m) | (m) | $107.55K* | (m) | $0.00 | (m) | $173.95K |
| 2023-03-31 | Reported | (m) | -$325.75K | (m) | (m) | (m) | (m) | -$372.98K | (m) | (m) | (m) | $255.77K |
| 2022-09-30 | Reported | (m) | -$179.73K | (m) | (m) | (m) | (m) | -$33.24K* | (m) | (m) | (m) | $79.75K |
| 2022-06-30 | Reported | (m) | -$232.74K | (m) | (m) | (m) | (m) | -$392.91K* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$5.01K | (m) | (m) | (m) | (m) | $6.29K | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$16.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$3.51K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$7.15M | (m) | (m) | (m) | (m) | -$5.89M | (m) | $634.19K | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$5.54M | (m) | (m) | (m) | (m) | -$2.95M | (m) | $0.00 | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$631.32K | (m) | (m) | (m) | (m) | -$446.92K | (m) | $0.00 | (m) | $690.57K |
| 2022-12-31 | Reported | (m) | -$657.02K | (m) | (m) | (m) | (m) | -$493.04K | (m) | (m) | (m) | $322.02K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |